← Human Trials & Peer-Reviewed Studies
Impact of messages on concomitant use of nicotine replacement therapy and cigarettes: a randomized trial on the Internet.
Plain-language guide to PMID 12814500 (2003): randomized controlled trial of Therapeutic nicotine (patch, non-peptide) in 2027 people.
Key Facts
- PMID
- 12814500
- Journal
- Addiction (Abingdon, England)
- Year
- 2003
- Study type
- Randomized Controlled Trial
- Authors
- Etter JF et al. (3 authors)
- DOI
- 10.1046/j.1360-0443.2003.00406.x
What This Study Did, in Plain Language
What Was Tested
Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.
To assess the impact of messages recommending the concomitant use of nicotine replacement therapy (NRT) and cigarettes on smokers' intention to quit smoking.
Who Took Part
The abstract describes 2027 people taking part.
The age groups tagged for this paper are teenagers, adults, middle-aged adults and older adults, both men and women.
A total of 2027 people who answered an e-mail sent to 9074 current and former smokers recruited on a smoking cessation website.
Participants were divided randomly into four groups, each of which received a unique message (in French) by e-mail.
How the Study Was Run
In design terms this was a randomized study.
Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.
The 'control' message said that nicotine replacement therapy (NRT) attenuates withdrawal symptoms in smokers who want to quit.
The 'temporary abstinence' message added that NRT can also be used by current smokers to manage smoke-free situations.
The 'side-effects' message discouraged concomitant use of NRT and cigarettes.
Perceived impact of these messages on motivation to quit smoking.
What Was Measured
PubMed files the paper under topics including Internet, Motivation, Nicotine, Nicotinic Agonists, Patient Education as Topic, Smoking Cessation and Surveys and Questionnaires.
What This Means in Plain Language
The paper is a randomized study of Therapeutic nicotine (patch, non-peptide) in 2027 people.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2003 (Addiction (Abingdon, England)), a journal based in England.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.